cyrilzakka/clinical-trials huggingface dataset:
Comparison of Pulse Wave and Blood Pressure Measurements Before, During and After Ergometry in Healthy Men

The objective of this randomized, controlled single blind study is to compare pulse wave and blood pressure measurements before, during and after exercise ergometry in healthy male subjects.

In a randomized single-blind study design the investigators explore how well blood pressure parameters calculated using a Pulse Transit Time-based method (device: SOMNOtouchTM RESP) match blood pressure parameters measured by a classic upper arm blood pressure cuff (Mobil-O-Graph® PWA) under standardized load conditions (ergometry).

In 30 healthy male subjects (age 18 - 40 years), cardiovascular parameters before, during and after a standardized load on a bicycle ergometer (half-lying position) are recorded with three different devices (Mobil-O-Graph® PWA versus SOMNOtouchTM RESP versus GeTeMed Vitaguard 3100) and compared.

Primary outcome is the difference of the systolic blood pressure values between the devices Mobil-O-Graph® PWA versus SOMNOtouchTM RESP during the three phases.

The Mobil-O-Graph® PWA blood pressure cuff is applied randomized to the arm with the previously determined higher or lower systolic blood pressure mean difference. The subjects are blinded to the results of the measurements during ergometry.

After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest period. Measurements are taken every two minutes with the Mobil-O-Graph® PWA; data acquisition with the SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 devices takes place continuously over a total duration of 72 minutes.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Healthy at the time of the examinations
* Inconspicuous anamnesis regarding cardiovascular diseases and bronchial asthma
* resting heart rate 50 to 100 beats per minute
* Normal blood pressure or appropriately treated and controlled hypertension (systolic blood pressure ≤ 140 mmHg and diastolic blood pressure ≤ 90 mmHg)

Exclusion Criteria:

* Acute or chronic (especially cardiovascular) diseases, including cardiac arrhythmia and vegetative regulatory disorders (recorded via anamnesis)
* Taking allopathic medication: digitalis, beta blockers, antiarrhythmics
* Bronchial asthma (recorded by anamnesis)
* Alcohol abuse
* Heart diseases NYHA class IV
* Blood pressure side difference ≥ 10mmHg
* Fever (\> 37,5°C)
Effect of Protein-nutrition Beverages on Muscle Protein Synthesis in Women

This study investigates whether a protein-nutrition beverage can increase muscle protein synthesis to a similar magnitude as a control beverage.

Potential participants will be screened, and if eligible, invited to participate. Body composition and physical activity level will be assessed during the initiation visit. During the trial visits, women receive a protein-nutrition beverage; muscle protein synthesis is assessed via blood analytes and muscle biopsies at rest and after exercise. Statistical analysis includes mixed model regression approach with change in muscle protein synthesis as the primary outcome.

Eligibility Criteria:
Inclusion Criteria:

1. Older women, 65 to 75 years of age
2. At least 5 years post-menopausal
3. Body mass index (BMI) 20.00-29.99 kg/m2
4. Maintenance of habitual diet, physical activity patterns, and body weight throughout the trial
5. Low to moderate habitual physical activity ( \> 3500 but \< 10,000 steps/d, no structured activity)
6. In general good health (stage I hypertension allowed - 140/90) on the basis of medical history; and taking no medication other than anti-hypertensives, selective serotonin-reuptake inhibitors, and/or statins (excluding simvastatin \[Zocor\] and atorvastatin \[Lipitor\])
7. Participant understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.
8. Participant can consume a protein drink in the allotted time frame of 10 minutes

Exclusion Criteria:

1. History or presence of clinically important renal or gastrointestinal disorders, diabetes mellitus (glucose \>126 mg/dL, fingerstick) or metabolic disease, unstable arrhythmia, angina, taking anti-diabetic, anti-inflammatory, platelet inhibitor, or anti-coagulant medications.
2. Vegan
3. Smoker
4. Overt osteoporosis and/or osteopenia and/or sarcopenia as determined by DXA
5. High physical activity or participating in regular structured exercise (\> 10,000 steps/d)
6. History of allergy, sensitivity, or strong dislike towards any of the components of the study products (dairy protein)
7. Use of an investigational drug product within the last 30 days
8. Having participated in an another infusion protocol in the past year
9. Individual has a condition the PI believes would interfere with her ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk
10. Subject does not understand English
Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant

The purpose of this study is to determine whether adding primidone will improve the metabolism of clopidogrel thereby increasing metabolite levels within the blood stream and platelet response to clopidogrel in patients who were previously found to lack adequate response to clopidogrel. This information could help overcome clopidogrel resistance in patients who are at risk for stroke or transient ischemic attack (TIA).


Eligibility Criteria:
Inclusion Criteria:

* Males and females aged 18 - 90 years who are clopidogrel resistant as determined by whole blood aggregometry
* Patients with a low risk of new cerebrovascular ischemic events as indicated by an Essen Stroke Risk Score of less than three

Exclusion Criteria:

* Any history of allergy or intolerance to either Plavix or clopidogrel
* Any history of allergy or intolerance to either Mysoline or primidone
* Any clinically significant abnormalities in complete blood count as determined by the investigator
* Use of any acute medications within the last two weeks or initiation of any non-study medications during the study period that would effect CYP enzymes or platelet function
* Use of tobacco products from 2 weeks prior to enrollment in the study and throughout the duration of the study
* Any planned surgical procedures during the study or 5 days after the study has ended
* History of alcoholism or alcohol abuse
* Participants who have had any alcohol consumption within 24 hours of a blood draw
* Previous stroke in past 3 months
* Participants who are or are planning to become pregnant
* Participants who of reproductive potential must agree to use a method of contraception for the duration of the study as well as 4 weeks after participation is complete
* Change in any medications that could affect liver enzymes or platelet aggregation throughout the study
* Compliance less than 80 % based on pill counts on two different study visits
Community-based Tai Chi, Balance, and Fall Risk

Aims: Examine the effects of a community Tai Chi program on measures of balance and sensorimotor function.

Methods: In a pre-test and post-test design, balance was measured in older adults (N=344; 73.4±7.4 years) with 30-second chair stand, timed-up and go, and 4-stage balance test following a 12-week community-based tai chi intervention. Balance measures and additional sensorimotor measures, including hip abductor electromechanical delay and hip proprioception, were measured in a smaller sample of older adults (n=11; 67.3±3.7 years).


Eligibility Criteria:
Inclusion Criteria:

* age 60 years or older
* ability to independently ambulate
* self-described concern with stability and/or mobility.

Exclusion Criteria:

* Neurological diagnosis
* Participants body weight exceeds \>450 pounds).
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors

This study is a single-center, single-arm phase I clinical trial. A total of 30 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study.

An "autologous tumor-infiltrating lymphocyte therapy" dosing regimen consisting of lymphodepleting chemotherapy (FC regimen: cyclophosphamide + fludarabine), infusion of autologous tumor-infiltrating lymphocyte injection, and interleukin-2 injection will be used.The study process is divided into: screening period, sampling and production period, clearing and chemotherapy period, treatment and observation period, and follow-up period


Eligibility Criteria:
Inclusion Criteria:

1. Voluntarily enrolled in the study, signed an informed consent form, and willing and able to comply with the study protocol
2. At least one lesion (preferably superficial lymph nodes) that has not been treated with radiation, has not received other local therapies, has access to tumor tissue, and can isolate at least a mass ≥ 1.0 g of tissue mass (either single lesion source or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes
3. Eastern Collaborative Oncology Group (ECOG) physical fitness status score of 0 or 1.

Exclusion Criteria:

1. Failure of surgery and/or radiation therapy to relieve spinal cord compression is not eligible for enrollment
2. People with uncontrolled tumor-related pain as judged by the investigator
3. Risk of major bleeding as assessed by investigators
4. Have interstitial pneumonia or clinically significant active pneumonia at screening, or other respiratory disease that severely affects lung function
5. Any active autoimmune disease 14 days prior to clear lymphatic chemotherapy, history of autoimmune disease, or disease requiring systemic steroid hormone or immunosuppressive drug therapy 6:History of allergic reaction to any component of the drugs to be used in the study (including but not limited to autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, interleukin-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40, antibiotics (beta-lactam antibiotics, gentamicin));

7：Women who are pregnant or breastfeeding; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year of the cell return.
OSS-IRM: Optimization of MRI Sequences in Healthy Volunteers

Using MRI, many technical parameters can be changed to optimize the diagnostic quality of the examination. The study is interventionnal because healthy volunteers are not supposed to have an MRI exam.

The primary objective of this study is to optimize the imaging protocols and to validate the choice of the technical parameters in healthy volunteers.

The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools.

Using MRI, many technical parameters (sequence, parameters in the sequence, reconstruction method, etc.) can be changed to optimize the diagnostic quality of the examination.

The primary objective of this study is to optimize the imaging protocols and to validate the choice of the technical parameters in healthy volunteers.

The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools.

Prospective, single-center, observational MRI study A screening visit is planned to check the inclusion/non inclusion criteria followed by an imaging visit during which the MRI examination will be performed.

Theses 2 visits are scheduled at the subject's convenience. The number of participations to the study is limited to 5 per year per subject.

Eligibility Criteria:
Inclusion Criteria:

* Male or female subject,
* Aged 18 or above

Exclusion Criteria:

* Patient with any surgical clip, external clips, or any other ferromagnetic device, that is contraindicated for use in MRI
* Claustrophobic patient
* Pregnancy
* Breastfeeding
* Patients subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty
* No healthcare insurance
The Study of Slip Pulse Feature Extraction Method Based on the Image Processing Technology for Traditional Chinese Medicine

The diagnoses processes of Traditional Chinese Medicine (TCM) focus on the following four main types of diagnoses methods consisting of inspection, listening and smelling, inquiry, and palpation. The most important one is palpation also called pulse diagnosis which is to measure wrist artery pulse by TCM doctor's fingers to detect patient's health state. The pulse diagnosis has three parts, namely 'Cun', 'Guan' and 'Chi', with the location. Wrist measurements correspond to different parts of the body's organs.

However, the pulse information is analyzed by TCM doctor's pulse diagnoses process, which is picked only a single waveform from a long-term pulse measured process and often discarded the other waveforms contained in the same information, e.g. Slippery Pulse waveform. The research object of this project is to divide the TCM diagnosis patients into two groups, one is the Slippery Pulse group and the other is a Normal Pulse group, in which 30 cases are collected in each group. The purpose of this project will integrate the TCM doctor's experiences and standardize them in order to construct an effective Slippery Pulse diagnosis system. It could refine Slippery Pulse diagnoses processes and reduce their diagnoses loading by using the proposed approach during this project. Therefore, we could carry out the research on feature extraction method of Slippery Pulse based on the image processing technology. We could extract the pulse characteristics of Slippery Pulse automatically from the many measurement signals and improve the automatic judging ability of the current pulse instrument to the Slippery pulse waveform. Provide important pulse information to the TCM doctors as an important reference for clinical diagnoses.


Eligibility Criteria:
Inclusion Criteria:

1. Already sign test consent permit.
2. More than 20-year-old.

Exclusion Criteria:

1. Can not accept acupuncture points stimulators.
2. Allergic to acupuncture needles.
Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale

Following a cryptogenic stroke, many patients are nowadays treated with the percutaneous closure of a patent foramen ovale (PFO), assuming that the aetiology of the stroke is secondary to a paradoxical embolism. After the PFO closure procedure a dual antiplatelet regimen is often prescribed for 3-6 months and several cardiologic and neurologic follow-up exams are scheduled in the first 12 months of follow-up. Usually a transthoracic +/- transoesophageal echocardiography (TTE +/- TEE) are performed at 6 months, however this kind of control is not systematically performed. In order to improve the clinical outcomes in this young patients' population, the investigators prospectively perform a complete cardiologic and neurologic follow-up program to all patients undergoing a successful percutaneous closure of a PFO.

The aim of these controls is to confirm the good position of the PFO-device, to confirm the absence of any residual right to left shunt or any significant atrial arrhythmias Furthermore this prospective follow-up will analyze the possible mechanisms leading to a cerebral stroke recurrence (e.g. size of the PFO, presence of an atrial septal aneurysm, presence of a residual shunt, size of the utilized closure device, ....).

At follow-up the following exams will be performed:

* at hospital discharge: chest X-ray +/- TTE + 7-days event loop record (ELR)
* at 6 months: clinical cardiologic and neurologic examination + TTE + TEE + 7-days ELR + trans-cranial doppler (TCD) with micro bubbles detection.
* at 1 year: clinical cardiologic and neurologic examination + TTE +/- TEE + 7-days ELR + trans-cranial doppler (TCD) with micro bubbles detection +/- cerebral MRI

Eligibility Criteria:
Inclusion Criteria:

* 18 years old patients
* signed informed consent
* all consecutive patients undergoing a successful percutaneous closure of a PFO secondary to a cryptogenic stroke

Exclusion Criteria:

* all patients with an alternative aetiology of the initial stroke
* all patients in whom the percutaneous closure of the PFO is contraindicated
* all patients with a known allergy to aspirin and or clopidogrel
Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia

To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.


Eligibility Criteria:
Inclusion Criteria:

Adult patients with at least 1 blood culture positive for Staphylococcus aureus were included within 1 to 7 days of blood culture sampling.

Exclusion Criteria:

* age younger than 18 years
* imprisonment
* proven or suspected pregnancy
* breastfeeding, epilepsy
* another bacteremia during the previous 28 days
* polymicrobial bacteremia (_\>3 microbes)
* history of allergy to any quinolone antibiotic
* previous tendinitis during fluoroquinolone therapy
* prior fluoroquinolone use for more than 5 days before randomization
* positive culture for Staphylococcus aureus only from a central intravenous catheter
* neutropenia (\<0.5 x 109/L) or failure to supply an informed consent
* patients with bacteremia due to methicillin-resistant S. aureus and a S. aureus strain resistant to any fluoroquinolone
* patients with meningitis at the time of randomization
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response in a school or work environment.


Eligibility Criteria:
Main Inclusion Criteria:

Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation.

Have a treatment history of an inadequate ADT response to at least 1 ADT (but not \> 3) for the current episode.

Have received a single, trial-approved, SSRI or SNRI at an adequate dose for ≥ 6 weeks prior to screening.

Are 18 to 35 years old at the time of consent (inclusive, and outpatients only).

Are (and will be) working 20 hours or more per week or a student taking 6 credit hours or more during the trial period, however minor deviations from the "part-time" concept may be acceptable on a case-by-case basis based on approval of the medical monitor.

Have a Hamilton Depression Rating Scale (HAM-D)- 17-item Total Score ≥ 18 at screening and baseline.

Have a Sheehan Disability Scale (SDS) 3-item mean score ≥ 5 at baseline.

Main Exclusion Criteria:

Subjects with any of the following current Axis I DSM-IV-TR diagnoses: delirium, dementia, amnestic, or other cognitive disorders; schizophrenia, schizoaffective disorder, or other psychotic disorders; bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified (NOS); eating disorders (including anorexia nervosa or bulimia); obsessive compulsive disorder; panic disorder; post-traumatic stress disorder; and attention deficit hyperactivity disorder.

Subjects with any of the following current Axis II DSM-IV-TR diagnoses: borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorders, or mental retardation.
ISOperistaltic Versus ANTIperistaltic Anastomosis After Laparoscopic Right Colectomy for Cancer

The study will provide a precise control compared to the two interventions (iso vs antiperistaltic anastomoses) with thorough measurements of the postoperative variables and complications to improve the evaluation of the surgical technique. It will also enable an evaluation of the quality of life after the procedures.


Eligibility Criteria:
Inclusion Criteria:

* The patient has given informed consent to participate
* No surgery contraindications
* Elective surgery
* No pregnancy or nursery during the study
* Older than 18 years
* Complete preoperative cancer staging
* Tumour characteristics:

  * Cecum, ascending, hepatic angle or transverse colon tumour confirmed by endoscopic biopsy
  * Radiologically resectable tumours
  * Absence of vascular, nervous or bone infiltration
  * T4 stages with near organ infiltration
  * Absence of peritoneal carcinomatosis
  * Absence of respiratory pathology that prevents for doing hydrogen breath test

Exclusion Criteria:

* Pregnancy
* Intestinal bowel disease like Crohn's disease or ulcerative colitis.
* Metastatic bone illness
* Previous abdominal surgery with bowel resection
* Malabsorption syndromes
Biological Sample Collection for Research and Biobanking

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to study different conditions and diseases by using cells from the body (such as skin or blood cells). NYSCF uses these samples to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store these samples for future use.

Through this research, scientists hope to identify future treatments or even cures.

Researchers at NYSCF study diverse diseases, conditions, and traits by creating "pluripotent" stem cells. These stem cells can become any cell in the human body, including cells that may be difficult, invasive, or even impossible to obtain directly. For example, researchers may create pancreatic insulin-producing cells to learn more about type 1 diabetes, or brain cells to learn more about Parkinson's disease.

Additionally, researchers perform genetic testing to learn more about DNA, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). A piece of DNA that determines the specific role of a cell is called a "gene." If the instructions in a gene are abnormal, this can lead to disease.

Participation in the study involves: (1) completion of a health questionnaire, (2) providing a skin and/or blood sample from which stem cells may be created, (3) possible collection of a saliva sample for genetic analysis, and (4) possible future follow-up to provide additional information or learn about other research studies.

This study is not a clinical trial.

Eligibility Criteria:
Inclusion Criteria:

Age

* 18 years or older or
* Minor with parent/guardian consent

Biological Sample Collection

* Able and willing to provide:

  * new samples of blood, skin, and/or saliva specifically for use in this study and/or
  * excess/leftover samples, cell lines, and/or derivatives that were (or will be) collected for reasons other than this study

Exclusion Criteria:

* Non-English speaking
* Wards of the state
* For skin samples collected specifically for this study: history of keloid formation, bleeding disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
* For blood samples collected specifically for this study: bleeding disorder, or other medical condition, if the subject's condition increases the risks associated with blood collection.
* For saliva samples: inability to produce sufficient saliva or has a condition that precludes sample collection (such as severe trismus).
* For prospective samples: refuse to adhere to NYSCF's and/or collaborating site's COVID-19 safety protocols during the COVID-19 pandemic.